Xilio Therapeutics Inc. (XLO)
NASDAQ: XLOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XLO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $53.40M
- P/E (TTM)
- 11.63
- EPS (TTM)
- $0.65
- Dividend yield
- None
- 52-week range
- 6.47 – 10.71
- Day range
- 7.07 – 7.60
- Volume / Avg
- 20.10K / 11.54K
- Beta
- —
- Shares outstanding
- 7.06M
52-week range
XLO stock today
Shares of Xilio Therapeutics (XLO) finished lower on Nov 20 at $7.56, a drop of 1.11% or $0.085 per share, versus the S&P 500's 3.70% decline. Shares are 29.4% below their 52-week high of $10.71, set on Nov 25, 2025 and 16.9% above the 52-week low of $6.47, in the middle of the past year's range. XLO is down 15.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.3%.
Xilio Therapeutics trades at 11.6x its trailing twelve-month earnings per share of $0.65.
Summary generated from market data by MetaCap's automated system. Methodology
About Xilio Therapeutics
Company profileXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Rene Russo BCPS, Pharm.D.
- Headquarters
- Waltham, MA
- Employees
- 76
- IPO year
- 2021
- Website
- xiliotx.com
Financial highlights
Full financialsIn fiscal 2025, Xilio Therapeutics generated $43.8 million in revenue, up 589.9% from fiscal 2024. Xilio Therapeutics reported a net loss of $35.0 million, compared with a loss of $58.2 million a year earlier. Operating margin was -95.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $43.77M | $6.34M | — | — | — |
| Growth | +589.88% | — | — | — | — |
| Net income | $-35.04M | $-58.24M | $-76.40M | $-88.22M | $-75.80M |
| EPS (diluted) | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$20.00+164.55%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.30 vs $-1.05
- Surprise
- +71.43%
XLO news
All XLO news- Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswire
- Xilio Therapeutics to Present at the Stifel 2026 Healthcare ConferenceGlobeNewswire
- Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLCGlobeNewswire
Xilio Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs XLO |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs XLO |
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs XLO |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs XLO |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs XLO |
| ALDXAldeyra Therapeutics Inc. | 0.84 | +16.39% | $50.70M | vs XLO |
| CLNNClene Inc. | 3.52 | +0.57% | $50.69M | vs XLO |
| KZIAKazia Therapeutics Limited ADR | 4.92 | -8.38% | $56.22M | vs XLO |
Indexes, lists and sector
Xilio Therapeutics stock FAQ
What is Xilio Therapeutics's stock price today?
XLO last traded at $7.56 as of Nov 20, 4:00 PM EST, down 1.11% on the day. Prices are delayed at least 15 minutes.
Does Xilio Therapeutics pay a dividend?
No. Xilio Therapeutics does not currently pay a regular cash dividend.
What is XLO's P/E ratio?
XLO trades at a trailing P/E ratio of 11.63.
Who is Xilio Therapeutics's CEO?
Dr. Rene Russo BCPS, Pharm.D. is the chief executive officer of Xilio Therapeutics Inc., which has about 76 employees.
Has XLO ever split its stock?
Yes. The most recent XLO stock split was a 1-for-14 split on Mar 16, 2026.
What is the XLO 52-week high?
The 52-week high for XLO is $10.71 and the 52-week low is $6.47. The stock is currently 29.4% below its high.